linjc16/ctgov huggingface dataset:
Fetus Anemia Diagnosis by Ultrasound Data Collection

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to diagnose anemia in fetuses through the use of ultrasound.

Official Title
-----------------
Fetus Anemia Diagnosis by Ultrasound Data Collection

Conditions
-----------------
Anemia in Fetus

Intervention / Treatment
-----------------
* Diagnostic Test: Ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women from 16th week to 41st week +6 days Singleton fetus Exclusion Criteria: All others

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fetus anemia diagnosis<br>Diagnosis of anemia in the fetus through use of ultrasound data collection | Diagnostic Test: Ultrasound<br>* Use of ultrasound device to diagnosis anemia in a fetus<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anemia diagnosis in fetus | Data collection from use of ultrasound will be analyzed through a laboratory algorithm to determine whether a fetus has anemia | One week |
Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes

Study Overview
=================
Brief Summary
-----------------
This is a phase III, multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of a two-day treatment with famciclovir (500 mg loading dose followed by 250 mg 12-hourly) to standard five-day treatment with famciclovir (125 mg 12-hourly) in patients with active recurrent genital herpes. This study is not recruiting patients in the United States.

Official Title
-----------------
Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes

Conditions
-----------------
Recurrent Genital Herpes

Intervention / Treatment
-----------------
* Drug: Famciclovir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of genital herpes Had at least 2 recurrences in past 12 months or 1 recurrence in past 6 months Exclusion Criteria: - Currently taking suppressive herpes antiviral therapy Females who are pregnant, breast feeding or planning to become pregnant during study History of allergy to famciclovir or similar products (e.g. aciclovir, valaciclovir) Other protocol-defined exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Famciclovir|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Estimated probability being not lesion-free(i.e. not healed) 5.5 elapsed days (132 hours) after patient self-initiation therapy. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability assessed by AEs. |  |  | 
| Time between recurrences of genital herpes. |  |  | 
| Proportion of aborted (i.e. lesions did not appear)genital herpes recurrences. Change from baseline in symptoms or impairment. Change form baseline in functioning or disability. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
genital herpes, herpes, famciclovir
Efficacy, Safety, and Tolerability of HTS-519 Insert in Patients With Toenail Fungus of the Big Toenail

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the efficacy, safety and tolerability of HTS-519 Inserts in the treatment of mild to moderate toenail fungus disease of the big toenail.

Detailed Description
-----------------
Open label, single-site

Official Title
-----------------
An Open-Label Phase 2 Study to Investigate the Efficacy, Tolerability, and Safety of the HTS-519 Insert in the Treatment of Subjects With Distal Lateral Subungual Onychomycosis of the Great Toenail

Conditions
-----------------
Onychomycosis

Intervention / Treatment
-----------------
* Drug: HTS-519 Insert


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and females 18 - 74 years of age inclusive Fungal toenail infection of one or both of the large (great) toenails The nail infection must be due to a dermatophyte, (mixed infections [dermatophyte and non-dermatophyte] are not allowed) Willingness not to have professional pedicures or application of any nail polish product or nail cosmetics to the toenails after the screening visit Exclusion Criteria: History of any significant chronic fungal disease other than onychomycosis or immunocompromised condition Any abnormalities of the nail or previous surgery of the toenail that could prevent a normal appearing nail if clearing of infection is achieved Significant confounding conditions as assessed by the study doctor Participation in any other trial of an investigational drug or device within 30 days or participation in a research study concurrent with this study No administration of systemic antifungal medications within 6 months prior to screening visit No application of prescription topical antifungal medications for toenail fungus within 3 months or other commercially available topical medications for toenail fungus applied directly to the toenails within 1 month prior to screening visit Tinea pedis (athlete's foot) that would require systemic treatment Other protocol-defined inclusion/exclusion criteria may apply

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HTS-519 Insert<br>Active treatment | Drug: HTS-519 Insert<br>* Maximum feasible dose of HTS-519 Insert per diseased nail<br>* Other names: HTS-519 Biodegradable Micro Insert;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment Related Adverse Events | Frequency and severity of Treatment Related Adverse Events | Up to 48 weeks |
National Health Interview Survey in Taiwan

Study Overview
=================
Brief Summary
-----------------
The major elements of the survey were sampling, questionnaire design, field survey and database construction. This survey incorporated the multistage stratified sampling scheme. Questionnaires include health status, utilization of health care, health behaviors, quality of life, and social economic status.

Detailed Description
-----------------
This survey took a representative sample from each county and municipality in Taiwan using a stratified multi-stage systematic sampling procedure. Within each county/municipality (stratum), samples were selected with probability proportional to population size. Questionnaire design was based on the needs of the Department of Health and Welfare and the public health professionals. Due to different age has different health problems, the questionnaires were divided into 3 parts: under 12, 23-64, and 65+ years. The response rate was 75% in 2013.

Official Title
-----------------
National Health Interview Survey in Taiwan

Conditions
-----------------
Public Health

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All the selected samples were to be interviewed. Exclusion Criteria: severely ill or too frail to answer; having cognitive problems; having hearing or speaking problems; or dementia.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health Status of the General Population | Survey on the general health of the nation in a specific time | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
public health
Endometrial Gene Expression Profile in Controlled Ovarian Stimulation Cycles With Premature Luteinization

Study Overview
=================
Brief Summary
-----------------
Previous studies have suggested that premature luteinization (PL)during controlled ovarian stimulation (COS) decreases the implantation rate due to a negative effect on the endometrium receptivity. This study aims to describe the impact on endometrial gene expression of PL in GnRH antagonist and GnRH agonist cycles.

Official Title
-----------------
Endometrial Gene Expression Profile in Controlled Ovarian Stimulation Cycles With Premature Luteinization

Conditions
-----------------
Premature Luteinization

Intervention / Treatment
-----------------
* Procedure: endometrial biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Oocyte donors Age between 18-35 years old BMI 18-29 NORMOGONADOTROPHICS PROGESTERONE ≥ 1.2 ng/ml on hCG day Exclusion Criteria: PolyCystic Ovarian Syndrome (PCOS) Endometriosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: endometrial biopsy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Health Related Quality of Life in Lung Transplantation in Strasbourg

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to study the quality of life in lung transplant patients. The cohort includes all of the surviving and transplanted patients at the New Civil Hospital in Strasbourg between 2008 and 2018. The main objective is to assess the quality of life of this cohort by two questionnaires which are the SF36 (generic score) and the saint Georges's questionnaire (specific score). The secondary objectives are the measurement of survival after lung transplantation, the comparison of the quality of life of these patients with that of the general population by the SF36 questionnaire, the search for perioperative factors influencing the quality of life and finally the search for an association between quality of life and socio-professional life.

Official Title
-----------------
Study of the Quality of Life in Surviving Lung Transplant Patients Between 2008 and 2018 by SF36 and St Georges's Questionnaires

Conditions
-----------------
Lung Transplantation

Intervention / Treatment
-----------------
* Behavioral: Questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Transplants survivors in Strasbourg hospital between 2008 et 2018 Patient able to answer a questionnaire in french Exclusion Criteria: Pregnancy Vulnerability Safeguard of justice, curatorship or tutorship Emergency situation Difficilty in understanding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Questionnaires|Use questionnaires ( SF36 questionnaire (generic score) and St Georges's questionnaire (specific score))|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health related quality of life | Score obtained by a questionnaire : SF36 | 12 month | 
| Health related quality of life | Score obtained by a questionnaire : St Georges | 12 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Health related quality of life, Lung transplantation, SF36, St Georges's Respiratory
Impact of Myofuntional Therapy Program on Increasing Tongue Strength and Improving Sleep Apnea

Study Overview
=================
Brief Summary
-----------------
This Research studies for compare muscle strength among OSA patients who treat with myofunctional therapy program in Rajavithi hospital

Official Title
-----------------
Impact of Myofuntional Therapy Program on Increasing Tongue Strength and Improving Sleep Apnea: a Randomized Controlled Trail

Conditions
-----------------
Obstructive Sleep Apnea

Intervention / Treatment
-----------------
* Other: myofunctional therapy program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who diagnose with Obstructive sleep apnea 18-65 years Exclusion Criteria: BMI>=35kg/m2 alcoholic and smoke use sleeping pill craniofacial syndrome hypertrophic tonsils grade 3+, 4+ severe comorbidity Use CAP

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Obstructive sleep apnea<br>myofunctional therapy program | Other: myofunctional therapy program<br>* Exercise oral cavity muscle<br>|
| No Intervention: control<br>standard treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare muscle strength | compare muscle strength before and after program by IOPI | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
myofunctional therapy, IOPI, Obstructive sleep apnea (OSA)
Associations Between Air Pollutants Exposures and Respiratory System Study

Study Overview
=================
Brief Summary
-----------------
Epidemiological investigations has suggested exposure to air pollution linked with respiratory disease, especially chronic obstructive pulmonary disease. However, the potential mechanisms of adverse effects remains scare. The present study will assess the association between air pollutants and respiratory related parameters to elucidate possible mechanisms.

Official Title
-----------------
Associations Between Air Pollutants Exposures and Respiratory System Study

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Long-term residents, aged >23 and <82 years Exclusion Criteria: Severe cardiopulmonary diseases, active inflammatory diseases, cancer

Ages Eligible for Study
-----------------
Minimum Age: 23 Years
Maximum Age: 82 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung Function indices were performed in peking university third hospital | Lung Function indices including FEV1(ml), FVC(ml),the ratio of FEV1/FVC et, al.. When we perform data analysis,these parameters will be expressed as the percentage of the predicted values based on the subject-specific sex, age,height and weight. | Repeated-measure study was conducted from November,2014 to January,2016,lung function was measured by every four months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inflammation related biomarkers were measured by flow cytometry | Inflammation related factors including IL,TNFa et, al. all biomarkers units are pg/ml. | Repeated-measure study was conducted from November,2014 to January,2016,biomarkers were measured by every four months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Obstructive Pulmonary Disease
Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS)

Study Overview
=================
Brief Summary
-----------------
Patients with severe CAR-T cell associated cytokine release syndrome (CRS) (defined as vasopressor dependent) will be treated with standard of care (SOC) + cytokine adsorption (6hourly for 24 hrs). Primary endpoint is the change in plasma IL-6 between 0 and 24 hrs.

Official Title
-----------------
Effectivity of Extracorporeal Cytokine Adsorption (Cytosorb) as Additive Treatment of CAR-T Cell Associated Cytokine Release (CRS) Syndrome and Encephalopathy Syndrome (CRES)

Conditions
-----------------
Cytokine Release Syndrome, CAR-T

Intervention / Treatment
-----------------
* Device: Cytosorb


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: severe CRS (> 3) and / or severe CRES (>3) AND - CRS/CRES onset < 6 hrs Exclusion Criteria: Heparine allergy contraindication for anticoagulation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Standard of care (SOC)<br> | |
| Experimental: Cyotosorb<br> | Device: Cytosorb<br>* extracorporeal cytokine adsorption<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IL-6 change |  | 24 hours |
Effect of Prebiotics on Intestinal Gas Production, Microbiota and Digestive Symptoms

Study Overview
=================
Brief Summary
-----------------
Non-absorbable, fermentable residues in the diet increase intestinal gas production and induce gas-related symptoms, such as flatulence, abdominal bloating and distention; however, prebiotics, which are also fermented by colonic bacteria have been shown to improve this type of symptoms. The aim is to demonstrate changes in metabolic activity of gut microbiota and colonic biomass induced by prebiotics. Healthy subjects (n=20) will be administered a prebiotic (Galacto-oligo-saccharide; 2.8 g/d) for 3 weeks; they will also receive a standard diet during three days. The following outcomes will be measured immediately before, at the beginning and at the end of the treatment: a) number of gas evacuations during daytime for 2 days on the standard diet, by means of an event marker; b) volume of gas evacuated via a rectal tube during 4 hours after a test meal, by means of a barostat; c) microbiota composition by fecal analysis.

Official Title
-----------------
Effect of Prebiotics on Intestinal Gas Production, Microbiota and Digestive Symptoms

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Dietary Supplement: Bimuno Galacto-oligo-saccharide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Exclusion Criteria: gastrointestinal symptoms recent (3 months) antibiotic intake recent (3 months) change of diet recent (3 months) gastroenteritis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Healthy subjects<br>Bimuno Galacto-oligo-saccharide administration 2.7 g/d x 3 weeks | Dietary Supplement: Bimuno Galacto-oligo-saccharide<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of daily anal gas evacuations |  | Change from beginning of treatment (mean of days 2 and 3) to end of treatment (mean of days 20 and 21) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Volume of anal gas evacuation |  | Change from beginning of treatment (day 3) to end of treatment (day 21) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intestinal gas, Healthy subjects, microbiota, prebiotics
System for Ocular Oxygen Measurement

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to demonstrate the ability of the OcuMetrics system to measure oxygen on the surface of the eye. Oxygen is important to the health of the cornea. The proposed instrument will take advantage of phosphorescent dyes that are sensitive to oxygen concentrations to monitor oxygen concentrations on the surface of the eye. This will have obvious applications in eye research and contact lens testing.

Conditions
-----------------
Normal

Intervention / Treatment
-----------------
* Device: Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Exclusion Criteria: contact lens wear in last 6 weeks Use of topical drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: No Arms<br>Project was withdrawn before starting | Device: Intervention<br>* Project was withdrawn before starting. There were no interventions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| oxygen tension measurement by new device is comparable with gold standard, but less variable and faster. |  | 2 weeks |